King's College London

Research portal

Manu Shankar-Hari

Manu Shankar-Hari

NIHR Clinician Scientist, Reader and Consultant in Intensive Care Medicine

Start date at Kings: 11/10/2010

Contact details:

Department

Research interests

Dr Manu Shankar-Hari's unique research perspective comes from combining a formal training in epidemiology and basic science (immunology). His translational research is deeply influenced by CA Janeway’s work on lymphocyte receptor diversity, and G Rose’s conceptual arguments entitled ‘Sick individuals and sick populations’, which is reflected in the research programme he leads on.

Manu's research explores ways to improve acute and longer-term outcomes in adult critically ill sepsis and ARDS patients, by linking the illness immunobiology to trial design.

Research aims

Immunobiology

  • Lymphocyte abnormalities during sepsis-related critical illness and in sepsis survivor populations
  • Immune phenotypes and immune recovery patterns during sepsis-related critical illness

 Epidemiology and trial design

  • Epidemiology of Sepsis and ARDS related critical illness
  • Causality, modifiable determinants and dominant mechanisms in critical illness

Principal (Chief) Investigator projects

The following projects are funded by grants from the NIHR and the EME programme

  • VACIRiSS Trial - Vaccination for immune recovery following sepsis (EudraCT Number -  2017-002236-17)

Sepsis survivors are at much higher risk of infection-related rehospitalisation and death. The aim of VACIRiSS trial is to evaluate the immunogenicity of single dose 13-valent conjugate pneumococcal vaccine in preventing infection related rehospitalisation or death in sepsis survivors and to collect outcome event data with necessary precision to inform future definitive trial design.

http://www.guysandstthomasbrc.nihr.ac.uk/microsites/vaciriss/

  •  Investigate the epidemiology of infection-related rehospitalisation and death in sepsis survivors

Outcomes after critical illness reflect a complex interplay between patient characteristics, risk factors for critical illness, treatments in the ICU, and critical illness itself. This study builds on routinely collected data in England and uses in-depth epidemiological features of infection related rehospitalisation and death to improve longer term outcomes. 

  • Defining ARDS and sepsis sub-phenotypes: a re-analysis of two trials to inform stratified medicine approach with future trials

Acute Respiratory Distress Syndrome (ARDS) and sepsis are the two most common illnesses in the critically ill, with increasing incidence and high mortality and many statisitically negative trials. This research programme aims to identify homogenous groups (sub-phenotypes) such as patients with clinical or biological features or treatment response characteristics to inform future trial design by enriching patient populations likely to benefit the most from interventions.

 

View all (76) »

Top downloads

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454